Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

2014-08-27 03:15:04 | BioPortfolio


In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Breast Cancer


vinflunine, alkylating agent of physician choice registered in cancer


Buenos aires




Pierre Fabre Medicament

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:15:04-0400

Clinical Trials [5888 Associated Clinical Trials listed on BioPortfolio]

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capeci...

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status. The antitumor characteristics an...

Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after ...

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy, such as vinflunine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from d...

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

The purpose of the study is to test how ketoconazole affects with handling of vinflunine by the body which might affect how much vinflunine is in the blood stream and for how long

PubMed Articles [20119 Associated PubMed Articles listed on BioPortfolio]

Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.

Factors influencing the adoption of genomic testing are poorly understood, which may lead to inequitable and suboptimal treatment in cancer patients. Oncotype DX (ODX) is one of the first and most wid...

Metastatic prostate cancer cells are highly sensitive to 3-bromopyruvic acid.

3-Bromopyruvate (3-BP), an alkylating agent and a glycolytic inhibitor, is a promising anticancer agent, which can be efficient also against multidrug-resistant cancer cells. The aim of this study was...

Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine.

Urothelial carcinoma of the bladder are rare but aggressive tumors with a high metastatic potential. The prognosis of these tumors has not drastically changed over the past 30 years, with an overall s...

The mechanism of anticancer action and potential clinical use of kaempferol in the treatment of breast cancer.

In the last century, natural compounds have achieved remarkable achievements in the treatment of tumors through chemotherapy. This inspired scientists to continuously explore anticancer agents from na...

Preventing ovarian failure associated with chemotherapy.

Alkylating chemotherapy is often used to treat pre-menopausal women for various malignancies and autoimmune diseases. Chemotherapy-associated ovarian failure is a potential consequence of this treatme...

Medical and Biotech [MESH] Definitions

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

An alkylating agent in cancer therapy that may also act as a mutagen by interfering with and causing damage to DNA.

More From BioPortfolio on "Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer"

Quick Search


Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Searches Linking to this Trial